Emerging role of an immunomodulatory protein secretoglobin 3A2 in human diseases.

Shioko Kimura, Shigetoshi Yokoyama, Aprile L Pilon, Reiko Kurotani

Journal: Pharmacology & therapeutics 2022;236():108112

PMID: 35016921

Free Full Text on PubMed Central View on PubMed

Abstract

Secretoglobin (SCGB) 3A2 was first identified in 2001 as a protein exhibiting similarities in amino acid sequence and gene structure to SCGB1A1, a multi-functional cytokine-like molecule highly expressed in airway epithelial Club cells that was the first identified and extensively studied member of the SCGB gene superfamily. SCGB3A2 is a small secretory protein of ~10 kDa that forms a dimer and a tetramer. SCGB3A2 is predominantly expressed in airway epithelial Club cells, and has anti-inflammatory, growth factor, anti-fibrotic, and anti-cancer activities that influence various lung diseases. This review summarizes the current understanding of SCGB3A2 biological functions and its role in human diseases with emphasis on its mechanisms of actions and signaling pathway.

Address: Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. Electronic address: [email protected].; Center for Molecular Toxicology and Carcinogenesis, Department of Veterinary and Biomedical Sciences, The Pennsylvania State University, University Park, PA 16802, USA.; APCBio Innovations, Inc., Rockville 20850, USA.; Biochemical Engineering, Graduate School of Science and Engineering, Yamagata University, Yonezawa, Yamagata 992-8510, Japan.

DOI: 10.1016/j.pharmthera.2022.108112

Link outs

Free resources

Full Text Sources:

Miscellaneous:

https://assays.cancer.gov/non-CPTAC-3520

Molecular Biology Databases:

https://glygen.org/publication/PubMed/35016921/

Subscription / membership required

Full Text Sources:

MeSH Terms: Cytokines, Humans, Respiratory System, Secretoglobins